EVOMEDIS GmbH, the Medical University of Graz (MedUni) and COREMED (JOANNEUM RESEARCH Forschungsgesellschaft mbH) Graz have initiated a strategic partnership with the aim of driving the change from wound care to wound healing through the introduction of innovative solutions.
EVOMEDIS has pledged an investment of 1,5 million euros over a period of two years in a joint project. The aim of this project is to develop EVOCellic, a ready-to-use wound healing solution for the treatment of burns and chronic wounds, offering cell-based therapy when the patient needs it, so there is no waiting time.
This partnership serves to deepen the existing collaboration between the parties, which is strengthened by the network of scientists, doctors and research institutions of the Medical Science City Graz (MSCG). EVOMEDIS GmbH, located at ZWT II, was founded in 2020 as a spin-out of the Würzburg company QRSKIN. The strategic intent was to create a “spin-in” company at MSCG that would work closely with local partners to develop new wound healing innovations leading to the first proof-of-concept clinical trials.
EVOCellic is a keratinocyte-based skin replacement made from allogeneic cells. It has been granted orphan drug designation (EU/3/22/2637) by the European Medicines Agency for the treatment of partial burns of the deep dermis and all skin. When EVOCellic is applied to a wound, it enables rapid and effective healing by stimulating the skin's natural regeneration process through the release of growth factors.
As part of the scientific collaboration, EVOCellic will undergo further optimization of the production process and the necessary preclinical tests by a team led by Prof. Lars Kamolz (Director of COREMED and Chair of Surgery). The next stage of GMP production adjustment is to be carried out in the GMP facility for new cell therapeutics (ATMPs) in the Department of Blood Group Serology and Transfusion Medicine at MedUni under the direction of Prof. Peter Schlenke.
